文献速递肿瘤 PET/CT

18F-氟昔洛韦PET/CT在前列腺癌治疗决策中的大样本单中心实践分析

18F-Fluciclovine PET/CT in Therapeutic Decision Making for Prostate Cancer: A Large Single-Center Practice-Based Analysis.
PubMed 文献 · Clin Nucl Med · 2021-01-01

PET/CT灵敏度93%、特异度63%,在73%的可评估患者中改变或影响了PET前管理计划,82%的实际管理与PET/CT后推荐一致。

要点

  • 18F-氟昔洛韦PET/CT在生化复发前列腺癌中灵敏度93%、特异度63%。
  • 73%的可评估患者PET/CT改变或影响了原管理计划,58%涉及治疗方式决策。
  • 82%患者实际管理与PET/CT后推荐一致,35%可评估患者计划中包含放疗。

核心结论

  • 在迄今最大单中心队列中,18F-氟昔洛韦PET/CT对生化复发前列腺癌的诊疗有临床管理决策影响力。
  • 尚需进一步研究评估基于PET/CT的管理改变是否与结局改善相关。

研究设计与样本

  • 回顾性队列研究,纳入2010年1月至2019年1月在本机构接受18F-氟昔洛韦PET/CT的根治性治疗后生化复发前列腺癌患者。
  • PET/CT结果与活检、常规影像和/或治疗反应比较,计算诊断性能及对治疗计划的影响。

主要发现

  • 灵敏度93%(95%CI 86%-96%),特异度63%(95%CI 45%-77%)。
  • 在已知PET/CT后管理推荐的患者中,73%的扫描结果改变或影响了PET前管理计划,58%的推荐涉及治疗方式决策。
  • 82%患者的实际管理与PET/CT后推荐一致。
  • 可评估患者中116例(35%)的计划包含某种形式的PET后放疗,其中95%针对PET阳性靶区接受放疗。

临床怎么用

  • 18F-氟昔洛韦PET/CT可用于生化复发前列腺癌的再分期评估,其结果常影响治疗方式选择。
  • PET/CT后推荐与实际管理一致性较高,支持将其纳入生化复发患者的诊疗决策流程。

局限性

  • 为单中心回顾性研究,结论外推需谨慎。
  • 原文未报告基于PET/CT的管理改变是否与患者结局改善相关,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

METHODS: We carried out a retrospective cohort study of patients with BR after primary treatment of PC who received imaging with 18F-fluciclovine PET/CT at our institution between January 2010 and January 2019. PET/CT results were compared with biopsy, conventional imaging results, and/or response to PC therapy. 18F-Fluciclovine PET/CT performance statistics and effects on treatment planning were calculated. RESULTS: A total of 328 patients with a median age of 71 years (range, 47-90 years) and median serum prostate-specific antigen level of 1.6 ng/mL (0.02-186.7 ng/mL) were included. Three hundred thirty-six 18F-fluciclovine PET/CT scans were analyzed and classified as positive (65%), negative (25%), or equivocal (10%) based on radiology reports. Sensitivity was 93% (95% confidence interval, 86%-96%) and specificity was 63% (95% confidence interval, 45%-77%). Of patients with known management recommendations post-PET/CT, scan results changed or influenced pre-PET/CT management plans in 73%, and 58% of recommendations involved treatment modality decisions. Overall, 82% of patients' actual management was concordant with post-PET/CT recommendations. Of evaluable patients, 116 (35%) had some form of post-PET radiotherapy included in their care plans, with 95% receiving radiotherapy at a PET-avid target. CONCLUSIONS: In the largest single-institutional cohort to date, 18F-fluciclovine PET/CT showed value in the workup of PC in the setting of BR, with noteworthy influence over clinical management decisions. Further studies are needed to evaluate whether PET/CT-based changes in management are associated with improved outcomes.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Dreyfuss AD, Ahn GS, Barsky AR, et al. 18F-Fluciclovine PET/CT in Therapeutic Decision Making for Prostate Cancer: A Large Single-Center Practice-Based Analysis. Clin Nucl Med. 2021. PMID: 33315672. doi:10.1097/RLU.0000000000003444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。